Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rare Disease Research Provides Insight, Advances in Rheumatic Disease

Allison Plitman  |  

Technological advances, including disease registries such as ACR’s RISE registry, are improving physicians’ ability to connect disparate patients with similar clinical symptoms, driving insights into both rare and common diseases.

Advancing Rheumatology Care Through State & Local Societies

Chris Adams, MD, FACP, FACR  |  

As his term as chair of the Affiliate Society Council draws to a close, Chris Adams, MD, FACP, FACR, reflects on the personal and professional rewards of volunteer leadership and the importance and impact of coordinated state-level advocacy efforts for the future of rheumatology.

High Opioid Prescription Rates Seen in Emergency Department-Treated Gout

  |  

Acute gout can be very painful, causing patients to seek treatment in the emergency department. A retrospective study of pain interventions for gout in Rhode  Island found that nearly 30% of patients received prescriptions for opioid medications over 30 months. Of these prescriptions, over 80% were for patients who had never been exposed to opioids…

Bringing Consistency to Gout Terms & Concepts

Larry Beresford  |  

The umbrella term crystalline disease covers arthritic conditions caused by deposition of crystals and associated inflammatory response, including erythema, edema and intense pain. The two most common crystal-induced arthropathies are gout, an arthritis secondary to inflammation caused by the presence of monosodium urate (MSU) crystals formed through high levels of serum urate, and calcium pyrophosphate…

Ticagrelor Lowers the Risk for OA Compared with Clopidogrel

  |  

Preclinical models have provided important insights into the pathogenesis of OA and potential pathways for therapeutic intervention, including adenosine. Ticagrelor and clopidogrel are both used in patients with coronary artery disease, but only ticagrelor increases extracellular adenosine levels. In this study, treatment with ticagrelor was associated with a 29% lower risk of developing OA than treatment with clopidogrel over five years of follow-up.